USPTO serial 88444536
CVCM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 30, 2020
- Examiner
- TENG, SIMON
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with CVCM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,700
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Tübingen, DE
Tübingen, DE
Tübingen, DE
TÜBINGEN, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer Fraser
Jennifer Fraser DYKEMA GOSSETT PLLC1301 K ST., NWSUITE 1100 WESTWASHINGTON, DC 20005Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical reagents and biomolecules, in particular biological macromolecules in the nature of nucleic acid for industrial or scientific purposes; Reagents for research purposes | ACTIVE | — |
| 005 | Chemical preparations for medical use, namely, for therapeutic and prophylactic treatment of neurological, neuromuscular, neurodegenerative, infectious and cardiovascular diseases, of autoimmune diseases and tumours, of allergies, of metabolic diseases, of heritable genetic diseases, and for therapies replacing proteins or enzymes; pharmaceutical preparations, namely, immunostimulants, in particular for human or veterinary medical purposes; pharmaceutical preparations, namely, vaccines, in particular for human or veterinary medical purposes; pharmaceutical preparations, namely, adjuvant immunostimulants; pharmaceuticals and medicaments containing biological macromolecules, in particular for human or veterinary purposes for the treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, for the treatment of infectious diseases, autoimmune diseases and tumours, for treatment of metabolic diseases and for treatment of heritable genetic diseases and for protein or enzyme replacement therapy; gene therapy products, namely, nucleic acid macromolecules for in vivo expression for human or veterinary medical use; Dietetic substances adapted for medical use, in particular substances for food supplements, namely, dietary food supplements | ACTIVE | — |
| 042 | Scientific and technological services, namely, technical biology consulting and scientific research services, in particular for identifying and characterizing biological macromolecules; pre-clinical and clinical testing of macromolecules | ACTIVE | — |
| 044 | Medical and veterinary services, in particular for therapeutic and preventative treatment of tumour diseases, infectious diseases, autoimmune disorders and allergies, for treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treatment of metabolic disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CureVac AG
- Other trademarks owned by CureVac AG
- Other trademarks owned by CureVac AG
- Other trademarks owned by CUREVAC SE
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CVCM
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 30, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 8, 2023 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jun 30, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 14, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 14, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 25, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 6, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 5, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 5, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 2, 2020 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Feb 22, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 22, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 22, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 10, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 10, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 10, 2020 | ALIE | ASSIGNED TO LIE | — |
| Feb 3, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 13, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 13, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 13, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 10, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 8, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 27, 2019 | NWAP | NEW APPLICATION ENTERED | — |